Developmental Malformations
Myelomeningocele
Mar. 11, 2024
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
Legend: c-NORSE, cryptogenic NORSE; IV, intravenous; IVIG, intravenous immunoglobulin; RSE refractory status epilepticus; SE, status epilepticus; SC, subcutaneous.
Adapted from:
Wickstrom R, Taraschenko O, Dilena R, et al. International consensus recommendations for management of new onset refractory status epilepticus (NORSE) incl. febrile infection-related epilepsy syndrome (FIRES): statements and supporting evidence. Epilepsia 2022;63(11):2840-64.
Hanin A, Jimenez AD, Gopaul M, Asbell H, et al. Trends in management of patients with new-onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis. Epilepsia. 2024 Aug;65(8):e148-e155.